Acro Biomedical (ACBM) Gross Margin (2017 - 2022)

Acro Biomedical has reported Gross Margin for 6 years, with the latest figure at 17.78% in Q4 2022.

• On a quarterly basis, Gross Margin fell 731.0% year-over-year to 17.78% in Q4 2022; TTM through Sep 2023 was 17.78%, a 749.0% decrease from a year earlier, with the FY2022 full-year figure at 21.34%, down 33.0% from the prior year.
• Gross Margin was 17.78% for Q4 2022 at Acro Biomedical, down from 25.63% in the prior quarter.
• The five-year high for Gross Margin was 29.65% in Q1 2021, with the low at 6.25% in Q4 2019.
• Average Gross Margin over 5 years is 16.81%, with a median of 16.0% recorded in 2021.
• The sharpest annual moves came in 2021 and 2022: Gross Margin soared 648 bps in 2021, then sank 731 bps in 2022.
• Over 5 years, Gross Margin stood at 10.0% in 2018, then plunged by 38 bps to 6.25% in 2019, then soared by 271 bps to 23.17% in 2020, then climbed by 8 bps to 25.08% in 2021, then retreated by 29 bps to 17.78% in 2022.
• The last three Gross Margin figures came in at 17.78% (Q4 2022), 25.63% (Q1 2022), and 25.08% (Q4 2021), per Business Quant data.